| Drug Name: | Paricalcitol (131918-61-1) |
|---|---|
| PubChem ID: | 5281104 |
| SMILES: | C[C@H](/C=C/[C@H](C)C(C)(C)O)[C@H]1CC[C@@H]2[C@@]1(CCC/C2=CC=C3C[C@H](C[C@@H](C3)O)O)C |
| InchiKey: | BPKAHTKRCLCHEA-UBFJEZKGSA-N |
| Therapeutic Category: |
| Molecular Weight (dalton) | : | 416.646 |
| LogP | : | 5.5606 |
| Ring Count | : | 0 |
| Hydrogen Bond Acceptor Count | : | 3 |
| Hydrogen Bond Donor Count | : | 3 |
| Total Polar Surface Area | : | 60.69 |
This panel provides information on interacting drugs and their ADRs along with references
| Interacting drug | Toxicity | Interaction Type | Mechanism | Reference |
|---|
This panel provides drug-protein interaction and their ADRs along with references
| Toxicity | Interacting Protein | Mechanism | Reference |
|---|---|---|---|
| Adverse Oversuppression Of Pth | Parathyroid hormone (Q03431) | Paricalcitol increased serum calcium levels and decreased PTH and bone alkaline phosphatase levels (all P [ ADR Type 1 ] | A placebo-controlled trial to evaluate immunomodulatory effects of paricalcitol |
| Galvanic Skin Response (Gsr) | Gastrin/cholecystokinin type B receptor (P32239) | CCK(B) receptor stimulation might reveal phenotype properties predictive of anxiety-related traits@ measurable through serum levels of C-peptide@which leads to Galvanic skin response (GSR). [ ADR Type 5 ] | Pentagastrin test for anxiety--psychophysiology and personality |
| Oversuppression Of Pth | Alkaline phosphatase (P05187) | Paricalcitol increased serum calcium levels and decreased PTH and bone alkaline phosphatase levels (all P [ ADR Type 1 ] | A placebo-controlled trial to evaluate immunomodulatory effects of paricalcitol |
This panel provides drug-food interactions and their ADRs along with references
| Food | Toxicity | Reference |
|---|
This panel provides information on metabolites and their ADRs along with references
| Metabolite | Toxicity | Place of Metabolism | Mechanism | Reference |
|---|
This panel provides information on drug category